Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.

Weinkove, R; McQuilten, ZK; Adler, J; Agar, MR; Blyth, E; Cheng, AC; Conyers, R; Haeusler, GM; Hardie, C; Jackson, C; Lane, SW; Middlemiss, T; Mollee, P; Mulligan, SP; Ritchie, D; Ruka, M; Solomon, B; Szer, J; Thursky, KA; Wood, EM; Worth, LJ; Yong, MK; Slavin, MA; Teh, BW

Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.

Weinkove, R McQuilten, ZK Adler, J Agar, MR Blyth, E Cheng, AC Conyers, R Haeusler, GM Hardie, C Jackson, C Lane, SW Middlemiss, T Mollee, P Mulligan, SP Ritchie, D Ruka, M Solomon, B Szer, J Thursky, KA Wood, EM Worth, LJ Yong, MK Slavin, MA Teh, BW

Permalink

Publisher:: AMPCo
Publication Type:: Journal Article
Citation:: The Medical journal of Australia, 2020, 212, (10), pp. 481-489
Issue Date:: 2020-06

Closed Access

	Filename	Description	Size
	mja2.50607.pdf	Published version	334.58 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Weinkove, R
dc.contributor.author	McQuilten, ZK
dc.contributor.author	Adler, J
dc.contributor.author	Agar, MR
dc.contributor.author	Blyth, E
dc.contributor.author	Cheng, AC
dc.contributor.author	Conyers, R
dc.contributor.author	Haeusler, GM
dc.contributor.author	Hardie, C
dc.contributor.author	Jackson, C
dc.contributor.author	Lane, SW
dc.contributor.author	Middlemiss, T
dc.contributor.author	Mollee, P
dc.contributor.author	Mulligan, SP
dc.contributor.author	Ritchie, D
dc.contributor.author	Ruka, M
dc.contributor.author	Solomon, B
dc.contributor.author	Szer, J
dc.contributor.author	Thursky, KA
dc.contributor.author	Wood, EM
dc.contributor.author	Worth, LJ
dc.contributor.author	Yong, MK
dc.contributor.author	Slavin, MA
dc.contributor.author	Teh, BW
dc.date.accessioned	2020-08-24T01:55:32Z
dc.date.available	2020-08-24T01:55:32Z
dc.date.issued	2020-06
dc.identifier.citation	The Medical journal of Australia, 2020, 212, (10), pp. 481-489
dc.identifier.issn	0025-729X
dc.identifier.issn	1326-5377
dc.identifier.uri	http://hdl.handle.net/10453/142294
dc.description.abstract	INTRODUCTION:A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS:During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT:This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY:Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	AMPCo
dc.relation.ispartof	The Medical journal of Australia
dc.relation.isbasedon	10.5694/mja2.50607
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	General & Internal Medicine
dc.subject.mesh	Humans
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Neoplasms
dc.subject.mesh	Hematologic Diseases
dc.subject.mesh	Consensus
dc.subject.mesh	Hematology
dc.subject.mesh	Medical Oncology
dc.subject.mesh	Australia
dc.subject.mesh	New Zealand
dc.subject.mesh	Practice Guidelines as Topic
dc.subject.mesh	Pandemics
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	Humans
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Neoplasms
dc.subject.mesh	Hematologic Diseases
dc.subject.mesh	Consensus
dc.subject.mesh	Hematology
dc.subject.mesh	Medical Oncology
dc.subject.mesh	Australia
dc.subject.mesh	New Zealand
dc.subject.mesh	Practice Guidelines as Topic
dc.subject.mesh	Pandemics
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	Australia
dc.subject.mesh	Betacoronavirus
dc.subject.mesh	Consensus
dc.subject.mesh	Coronavirus Infections
dc.subject.mesh	Hematologic Diseases
dc.subject.mesh	Hematology
dc.subject.mesh	Humans
dc.subject.mesh	Medical Oncology
dc.subject.mesh	Neoplasms
dc.subject.mesh	New Zealand
dc.subject.mesh	Pandemics
dc.subject.mesh	Pneumonia, Viral
dc.subject.mesh	Practice Guidelines as Topic
dc.title	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
dc.type	Journal Article
utslib.citation.volume	212
utslib.location.activity	Australia
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-08-24T01:55:28Z
pubs.issue	10
pubs.publication-status	Published
pubs.volume	212
utslib.citation.issue	10

Abstract:

INTRODUCTION:A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS:During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT:This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY:Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142294